Trial reportAnnals of the rheumatic diseases2003
Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk.
Trial report in Annals of the rheumatic diseases, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis.Arthritis research & therapy · 2006Pooled it
- The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus.Clinical rheumatology · 2010Trial
- Combination therapy with steroids and mizoribine in juvenile SLE: a randomized controlled trial.Pediatric nephrology (Berlin, Germany) · 2010Trial
- Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria.Rheumatology international · 2006Trial
- Mycophenolate mofetil: an update on its mechanism of action and effect on lymphoid tissue.Frontiers in immunology · 2024Article
- B cells in autoimmune hepatitis: bystanders or central players?Seminars in immunopathology · 2022Review
- New insights into the role of antinuclear antibodies in systemic lupus erythematosus.Nature reviews. Rheumatology · 2020Review
- An Update on Antibodies to Necleosome Components as Biomarkers of Sistemic Lupus Erythematosus and of Lupus Flares.International journal of molecular sciences · 2019Review
- Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus.Clinical rheumatology · 2019Article
- Rheumatoid arthritis in Latin America: the importance of an early diagnosis.Clinical rheumatology · 2015Review
- Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus.Arthritis research & therapy · 2012Article
- Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.Arthritis research & therapy · 2012Review
- Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- A novel means to demonstrate early efficacy of a product in systemic lupus erythematosus.Current rheumatology reports · 2007Article
- Can mycophenolate mofetil substitute cyclophosphamide treatment of pediatric lupus nephritis?Pediatric nephrology (Berlin, Germany) · 2007Review
- [Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Comment on the use of mycophenolic acid for systemic lupus erythematosus].Zeitschrift fur Rheumatologie · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic lupus erythematosus (SLE) is characterised by the presence of antibodies to double stranded DNA (dsDNA), which are involved in the pathogenesis of SLE. Previous studies showed that at least two thirds of patients develop a clinical relapse within six months after a significant rise in the anti-dsDNA level, and most relapses were prevented by the administration of corticosteroids at the time of the rise.
objectiveTo determine whether mofetil mycophenolate (MMF) can prevent a clinical relapse without the side effects associated with corticosteroids.
methods36 patients with SLE were examined monthly to determine whether a rise in anti-dsDNA level had occurred. A rise was defined as an increase of 25% of the level of the previous sample of at least 15 IU/ml within a four month period. After a rise patients were treated with MMF 2000 mg daily for six months. Patients were monitored monthly for the occurrence of a clinical relapse and to assess the serological activity and state of activation of CD4+, CD8+, and CD19+ lymphocyte subsets.
resultsAnti-dsDNA rose in 10 patients. Treatment with MMF was started in all these patients, and after six months no clinical relapse had occurred. Side effects were minimal. Antibodies to dsDNA decreased during the treatment (p<0.001), associated with a decrease in the state of activation of CD19+ lymphocytes. No changes were found in the state of activation of CD4+ or CD8+ lymphocyte subsets.
conclusionAdministration of MMF after a rise in antibodies to dsDNA is well tolerated, decreases anti-dsDNA and B cell activation, and seems to prevent the occurrence of a clinical relapse in patients with SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.